DexCom (DXCM)
(Delayed Data from NSDQ)
$130.71 USD
-3.59 (-2.67%)
Updated Apr 19, 2024 04:00 PM ET
After-Market: $130.72 +0.01 (0.01%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth B Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$130.71 USD
-3.59 (-2.67%)
Updated Apr 19, 2024 04:00 PM ET
After-Market: $130.72 +0.01 (0.01%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth B Momentum C VGM
Zacks News
3 Innovative Stocks to Buy Before Earnings Amid the Market Pullback
by Benjamin Rains
Long-term investors are often well-served to buy stocks amid bouts of weakness.
Reasons to Retain DexCom (DXCM) Stock in Your Portfolio for Now
by Zacks Equity Research
DexCom (DXCM) continues to raise optimism among investors, owing to its strong product portfolio.
Zacks Industry Outlook Highlights Edwards Lifesciences, DexCom and STERIS
by Zacks Equity Research
Edwards Lifesciences, DexCom and STERIS have been highlighted in this Industry Outlook article.
DexCom (DXCM) Stock Moves -1.16%: What You Should Know
by Zacks Equity Research
In the latest trading session, DexCom (DXCM) closed at $134.56, marking a -1.16% move from the previous day.
3 Medical Instruments Stocks to Buy Amid Improving Industry Trends
by Urmimala Biswas
The Zacks Medical - Instruments industry is expected to gain from the rising adoption of smart healthcare options, including genAI. However, supply issues and staffing shortages continue to disrupt growth. EW, DXCM and STE appear well-poised to brave the challenges.
DexCom (DXCM), MD Revolution Unite to Boost Diabetes Management
by Zacks Equity Research
DexCom (DXCM) and MD Revolution collaborate to integrate Dexcom's continuous glucose monitoring systems with MD Revolution's remote care management platform to boost remote diabetes management.
Is DexCom (DXCM) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how DexCom (DXCM) and Anika Therapeutics (ANIK) have performed compared to their sector so far this year.
Should First Trust Growth Strength ETF (FTGS) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for FTGS
Why the Market Dipped But DexCom (DXCM) Gained Today
by Zacks Equity Research
In the most recent trading session, DexCom (DXCM) closed at $139.94, indicating a +0.73% shift from the previous trading day.
DexCom, Inc. (DXCM) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
DexCom (DXCM) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
DexCom (DXCM) Falls More Steeply Than Broader Market: What Investors Need to Know
by Zacks Equity Research
In the closing of the recent trading day, DexCom (DXCM) stood at $136.65, denoting a -0.94% change from the preceding trading day.
Tenet (THC) Divests Six Hospitals, Sustains Divestiture Spree
by Zacks Equity Research
Tenet Healthcare (THC) completes the sale of six California hospitals, four to UCI Health and two to Adventist Health, to refine the portfolio and reduce debt burden.
DexCom (DXCM) Upgraded to Buy: What Does It Mean for the Stock?
by Zacks Equity Research
DexCom (DXCM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
DexCom (DXCM) Hits 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Investors are optimistic about DexCom's (DXCM) strong product portfolio.
DexCom (DXCM) Stock Moves -0.12%: What You Should Know
by Zacks Equity Research
In the latest trading session, DexCom (DXCM) closed at $139.93, marking a -0.12% move from the previous day.
Has DexCom (DXCM) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Here is how DexCom (DXCM) and Anika Therapeutics (ANIK) have performed compared to their sector so far this year.
Compelling Reasons to Hold on to UnitedHealth Group (UNH) Stock
by Zacks Equity Research
UnitedHealth Group (UNH) remains well-poised for growth on the back of improved premiums, acquisitions and partnerships, an in-demand telehealth services suite and solid cash-generating abilities.
DexCom, Inc. (DXCM) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Zacks.com users have recently been watching DexCom (DXCM) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
DexCom (DXCM) Stock Sinks As Market Gains: Here's Why
by Zacks Equity Research
DexCom (DXCM) closed at $134.17 in the latest trading session, marking a -0.41% move from the prior day.
Reasons to Retain DexCom (DXCM) Stock in Your Portfolio for Now
by Zacks Equity Research
DexCom (DXCM) continues to raise optimism among investors, owing to its strong product portfolio.
Encompass Health (EHC) Up 42% in a Year: What Lies Ahead?
by Zacks Equity Research
Encompass Health (EHC) remains well-poised for growth on the back of sustained top-line growth, an expanding healthcare facility portfolio and robust cash-generating abilities.
Buy 5 Medical Devices Stocks for a Stable Portfolio in 2024
by Nalak Das
We have narrowed our search to five Medical Instruments stocks with strong potential for 2024. These are: AORT, TMDX, DXCM, SWAV, EW.
Is It Worth Investing in DexCom (DXCM) Based on Wall Street's Bullish Views?
by Zacks Equity Research
According to the average brokerage recommendation (ABR), one should invest in DexCom (DXCM). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?
Zacks Investment Ideas feature highlights: Tenet Healthcare and HCA Healthcare
by Zacks Equity Research
Tenet Healthcare and HCA Healthcare are part of the Zacks Investment Ideas article.
Medical Devices ETF Hits 52-Week High: Stocks to Watch
by Bryan Hayes
Historically viewed as a defensive area, health care also boasts many growth aspects and benefits from advances in technology.